[ad_1]
Citizen – Riyadh
The FDA has explained that the drug Larotrectinib Vitrakvi serves a specific segment of cancer patients, but not all.
The FDA announced in a statement released today that some local and international media had recently approved the registration of Larotrectinib, a drug known as Vitrakvi, intended to treat certain types of cancer. News and news to talk about the benefits of drugs, to the point of suggesting the ability of this drug to treat complete tumors.
The drug "Larotrectinib Vitrakvi" acts innovatively by preventing the growth of tumors caused by a rare genetic defect (genetic mutation), causing certain cancers, which allows the drug to treat and treat a specific segment of patients, All patients with cancer.
The drug has received accelerated accreditation from the FDA, a measure adopted by the WHO for drugs that work in innovative ways or that could form the nucleus of a promising therapeutic future.
The study included 55 patients, including 12 patients under 18 years of age with rare genetic mutation (NTRK). The response to the drug in the months The first nine were good, reaching 73% of patients but decreasing gradually to 39% after the first year, highlighting the most significant adverse effects observed in patients who took this drug and the most common such that fatigue, nausea, vomiting, etc. Diarrhea and constipation
The SFDA said that options and treatment methods for cancer patients were growing. They will be available once they have been subjected to studies on safety and security, confirming that they are following scientific developments related to drugs or therapeutic methods and seeking to provide the patient with drugs and medicines. safe and effective treatment methods.
[ad_2]
Source link
